ROBERT PETER GALE, M.D., Ph.D.
This content is PDF only. Please click on the PDF icon to access.
Although leukemia is not a common disease, it has been a model for progress in modern cancer chemotherapy. Less than 30 years ago hematologists questioned whether patients with acute myelogenous leukemia should be treated (1). In the ensuing years substantial and important advances have been made, mostly within the past 10 years. Now, 60% to 80% of patients achieve a remission with intensive induction chemotherapy (1-10). Cytarabine and daunorubicin are the most effective drugs, but thioguanine, amsacrine, and high-dose cytarabine are also useful.
Once remission is achieved, the next objective is to prevent leukemic relapse; this has proved difficult. Several
GALE RP. Progress in Acute Myelogenous Leukemia. Ann Intern Med. ;101:702–705. doi: 10.7326/0003-4819-101-5-702
Download citation file:
Published: Ann Intern Med. 1984;101(5):702-705.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use